Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PHILADELPHIA, Feb. 19, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carismatx.com.
Investors:Shveta Digheinvestors@carismatx.com
Media Contact:Julia Stern(763) 350-5223jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-hc-wainwright-3rd-annual-cell-therapy-virtual-conference-302379463.html
SOURCE Carisma Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering. Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos How one company is revolutionizing the way we use everyday water The diagnostics company's IPO follows the successful debut of fintech companies like Chime Financial and Circle Internet Group, and will test whether investors are ready to embrace biotech companies despite declines in the sector for the last six months. Here's what to know about the listing. Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine. Through molecular analysis, Caris specializes in cancer diagnosis and treatment. According to a recent filing to the Securities and Exchange Commission (SEC), the Irving, Texas-based company currently has over 1,700 employees and over 100 biopharmaceutical partners. The company incurred net losses of $281.9 million and $341.4 million in 2024 and 2023, respectively, on revenue of $412.3 million and $306.1 million. It is expecting additional losses in the future. Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Caris Life Sciences will trade its stock under the ticker CAI. CAI shares were priced at $21, above their previously planned range. The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion. CAI will trade its shared on the Nasdaq Global Select Market. Caris Life Sciences's IPO will offer 23,529,412 shares. Founder and CEO Halbert is also set to retain 41.7% of ownership following the IPO. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss. In five years, the stock has soared by close to 480%, which would have turned a $20,000 investment into approximately $116,000. The GLP-1 market is still in its early growth stages, and there's plenty of room for more companies to make names for themselves. While Eli Lilly is a safe bet to invest in right now, if you want a position in stocks that may have considerably more upside in the GLP-1 market, there are two names you should take a closer look at today: Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT). The big excitement surrounding Viking is it has a GLP-1 treatment that could be a viable option for weight loss. VK2735 isn't an approved treatment yet, but it has been showing encouraging results in early-stage trials. In data released last year, a phase 2 trial showed that the drug was able to help patients lose up to 14.7% of their body weight after 13 weeks, without signs of any plateau, suggesting further weight loss could be possible. Phase 3 trials are set to begin this year. Meanwhile, Viking is also working on an oral version of the treatment, which is currently in phase 2 trials. The phase 1 data from that looked solid, with trial participants losing up to 8.2% of their body weight after 28 days. The risk with Viking is that it isn't generating revenue today, and it doesn't have any approved products. It has incurred a net loss totaling $128 million over the trailing 12 months, and there's a real possibility that those losses could deepen as it spends more on clinical trials. If VK2735 isn't successful and doesn't obtain approval from regulators, the stock could nosedive, which is the biggest concern for investors. Investors have largely looked past Viking this year, as the healthcare stock is down 35% (as of June 13), pulling its market cap down to less than $3 billion. However, if there's encouraging clinical data to come out in the future, that could trigger a rally in Viking's stock. This is a company that has a lot of upside, and if you're OK with taking on some risk, this may be a good stock to invest in a modest amount of money into. Altimmune is similar to Viking, but it's much smaller in market capitalization, worth less than $600 million. It hasn't been as popular of an option for investors, but it's an investment that may have even greater upside, given its more modest valuation. It also has a promising GLP-1 product that investors are bullish on: pemvidutide. In a phase 2 trial, participants lost an average of 15.6% of their body weight after a period of 48 weeks on the highest dosage (2.4 mg). The company doesn't have an oral version in development, but it is also testing pemvidutide as a treatment for other conditions, including metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol liver disease. Altimmune generates limited revenue (primarily coming from grants and contracts), and until and unless it obtains approval for pemvidutide, that's likely to stay this way. Over the past four quarters, its losses have totaled $90 million, and it has burned through more than $80 million just from its day-to-day operating activities. With around $150 million in cash and short-term investments, it's adequately funded, but there is high likelihood of share offerings being necessary in the future, and dilution is a real concern for investors. If pemvidutide becomes a success, Altimmune could easily double or triple in value and potentially be an acquisition target for a larger healthcare company seeking opportunities in GLP-1. There's risk with Altimmune, but there could also be tremendous upside. If you can stomach the uncertainty, you may want to consider taking a chance on the stock. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 34 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on June 16, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock option awards have an exercise price of $51.87 per share, the closing price of PTC's common stock on June 16, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. ABOUT PTC THERAPEUTICS, is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit and follow on Facebook, X, and LinkedIn. For more information please contact: Investors:Ellen Cavaleri+1 (615) 618-8228ecavaleri@ Media:Jeanine Clemente+1 (908) 912-9406jclemente@ View original content to download multimedia: SOURCE PTC Therapeutics, Inc. Sign in to access your portfolio
